These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

356 related items for PubMed ID: 2570698

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism.
    Gaedigk A, Blum M, Gaedigk R, Eichelbaum M, Meyer UA.
    Am J Hum Genet; 1991 May; 48(5):943-50. PubMed ID: 1673290
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype.
    Tyndale R, Aoyama T, Broly F, Matsunaga T, Inaba T, Kalow W, Gelboin HV, Meyer UA, Gonzalez FJ.
    Pharmacogenetics; 1991 Oct; 1(1):26-32. PubMed ID: 1844820
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Extremely slow metabolism of amitriptyline but normal metabolism of imipramine and desipramine in an extensive metabolizer of sparteine, debrisoquine, and mephenytoin.
    Brøsen K, Gram LF, Kragh-Sørensen P.
    Ther Drug Monit; 1991 Mar; 13(2):177-82. PubMed ID: 2053127
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Are poor metabolisers of sparteine/debrisoquine less pain tolerant than extensive metabolisers?
    Sindrup SH, Poulsen L, Brøsen K, Arendt-Nielsen L, Gram LF.
    Pain; 1993 Jun; 53(3):335-339. PubMed ID: 8351162
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Sparteine oxidation polymorphism: phenotyping by measurement of sparteine and its dehydrometabolites in plasma.
    Paar WD, Schuhler H, Fimmers R, Dengler HJ.
    Eur J Clin Pharmacol; 1989 Jun; 36(6):555-60. PubMed ID: 2590312
    [Abstract] [Full Text] [Related]

  • 36. In vitro metabolism of sparteine by human liver: competitive inhibition by debrisoquine.
    Otton SV, Inaba T, Mahon WA, Kalow W.
    Can J Physiol Pharmacol; 1982 Jan; 60(1):102-5. PubMed ID: 7066751
    [Abstract] [Full Text] [Related]

  • 37. Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine.
    Bertilsson L, Dengler HJ, Eichelbaum M, Schulz HU.
    Eur J Clin Pharmacol; 1980 Feb; 17(2):153-5. PubMed ID: 7371707
    [Abstract] [Full Text] [Related]

  • 38. Polymorphic drug oxidation in humans.
    Eichelbaum M.
    Fed Proc; 1984 May 15; 43(8):2298-302. PubMed ID: 6714436
    [Abstract] [Full Text] [Related]

  • 39. The genetic control of sparteine and debrisoquine metabolism in man with new methods of analysing bimodal distributions.
    Evans DA, Harmer D, Downham DY, Whibley EJ, Idle JR, Ritchie J, Smith RL.
    J Med Genet; 1983 Oct 15; 20(5):321-9. PubMed ID: 6644761
    [Abstract] [Full Text] [Related]

  • 40. The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: a meta-analysis.
    Christensen PM, Gøtzsche PC, Brøsen K.
    Eur J Clin Pharmacol; 1997 Oct 15; 51(5):389-93. PubMed ID: 9049580
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.